Hyperprolactinaemia
also: Hyperprolactinemia
2 drugs5,970 FAERS reportsMedDRA PT
GET
/api/v1/reaction/hyperprolactinaemiaReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D006966
Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)
Source: U.S. National Library of Medicine — MeSH (Hyperprolactinemia)
Drugs reporting Hyperprolactinaemia (2)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Risperidone4,4653.4%
- 2Paliperidone1,5052.9%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Abnormal Weight Gain2 shared · 0.67
- Galactorrhoea2 shared · 0.67
- Gynaecomastia2 shared · 0.50
- Extrapyramidal Disorder2 shared · 0.17
- Psychotic Disorder2 shared · 0.10
- Injury2 shared · 0.05
- Weight Increased2 shared · 0.01
- Somnolence2 shared · 0.01
- Product Use In Unapproved Indication2 shared · 0.01
- Insomnia2 shared · 0.00
Literature
Recent PubMed references pinned to Hyperprolactinemia as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia.Pituitary · 2026 · Zerbinati L, Cristilli G, Valier B, et al.PMID 42149330DOI 10.1007/s11102-026-01693-7
- Prolactinomas treated with dopaminergic agonists: behavior in different moments of life.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026 · Carneiro MS, Garmes HM, Pravatta-Rezende G, et al.PMID 41988239DOI 10.61622/rbgo/2026rbgo9
- Vitamin D Adequacy Conditions the Prolactin-Suppressive Effect of Metformin in Men Receiving Prolactin-Elevating Medications.Nutrients · 2026 · Krysiak R, Kowalcze K, Cangelosi G, et al.PMID 41978113DOI 10.3390/nu18071062
- The cross-talk between prolactin and growth hormone in pituitary adenomas.Best practice & research. Clinical endocrinology & metabolism · 2026 · Giraldi EA, McCord M, Ioachimescu AG, et al.PMID 41951532DOI 10.1016/j.beem.2026.102101
- Premature utilization of MRI in the workup of mild hyperprolactinemia.PloS one · 2026 · Mann JA, Galloway J, Ghaznavi S, et al.PMID 41950269DOI 10.1371/journal.pone.0346134
- Traditional Chinese medicine for antipsychotic-induced hyperprolactinemia: A comprehensive review of ethnopharmacological foundations, mechanistic insights, and network pharmacology perspectives.Journal of ethnopharmacology · 2026 · Sun X, Gao Y, Zhang L, et al.PMID 41932665DOI 10.1016/j.jep.2026.121623
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.